Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
2014 ◽
Vol 32
(15_suppl)
◽
pp. 5020-5020
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5068-5068
◽
2011 ◽
Vol 29
(27)
◽
pp. 3651-3658
◽
2014 ◽
Vol 32
(4_suppl)
◽
pp. 212-212
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5003-5003
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 5067-5067
2014 ◽
Vol 32
(15_suppl)
◽
pp. 5088-5088